genomic sequencing

Following feedback from Higher Biology students, this short revision episode aims to provide a quick summary of some of the key points from the Genomic Sequencing Key Area. This episode aims to supplement your revision and should not be seen as a replacement for other revision/retrieval techniques.

This episode is based on the Genomic Sequencing key area of the SQA Higher Biology Course.

You can ask questions or get in touch  via @BiologyHigher on Twitter

This podcast is sponsored by Leckie textbooks, revision guides and practice papers; everything you need to learn, review and prepare for your SQA Exams. Browse the books at www.leckiescotland.co.uk

You can also find the Leckie store on Amazon HERE

Thanks also to Education Scotland for their support.

YoungScot Rewards Code: MY3VC78X

The rise of genomic sequencing and use of novel agents in the new standard of cancer care has created new challenges in recognizing and managing toxicities.

In this episode, we are joined by Dr. Ian Olver, medical oncologist, bioethicist, researcher and current Professorial Research Fellow in the School of Psychology at the University of Adelaide, to discuss strategies and tools to support community oncologists in keeping patients on effective drugs by better managing the associated toxicities.

Learn more about our partners at VieCure.



The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.

In this week's podcast we chat with Peter Crock, CEO & Chair of Cann Group & MCIA about the Cannabis and "Big Pharma," GMP and changing regulations, Cannabis companies and their interface with the regulator, Cann's future product focus, Genomic sequencing and Accelerated cannabis breeding.

Cann Group:
https://www.canngrouplimited.com/

MCIA:
https://mcia.org.au/

Alt Med:
https://altmed.com.au/

Carlos Bustamante is an expert in genomics—the study of genetic variation and its effects on the living world. He says genomics holds tremendous promise but, so far, virtually all sequenced DNA comes from European blood lines and this presents a problem.

Without greater diversity in the genomic data that is collected, he notes that we cannot fully reap the benefits of this knowledge, particularly in areas such as healthcare.

"Genomics is the new oil," Bustamante says, of the opportunities that lie ahead. It's being used for everything from studying rare diseases to developing more effective drugs. Before its potential can be fully realized,however, genomics will have to address its diversity problem. The more genetic variants that are represented in the genomic data collected, the better equipped we'll be to understand and improve human health.

Join host Russ Altman and geneticist Carlos Bustamante for a peek into the wonders of genomics.

You can listen to the Future of Everything on Sirius XM Insight Channel 121, iTunes, SoundCloud and Stanford Engineering Magazine.

Connect With Us:

Episode Transcripts >>> The Future of Everything Website

Connect with Russ >>> Threads or Twitter/X

Connect with School of Engineering >>> Twitter/X

Discussion of H7N9 influenza virus transmission from poultry to humans in China.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv